Pureos Bioventures — 2022 Investments
5 investments dated 2022 · listed companies and verified rows first · show all
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in
Co-investorsredalpineSamsung VenturesVI Partnersb2ventureKinled Holding
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.
AI & Machine LearningBiotechDeep Tech
Rodrigo Vazquez-LombardiinSai Reddyin
Co-investorsNovo Holdings
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedSanofi VenturesSunstone CapitalEQT Life Sciences+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ariceum TherapeuticsTridek-One
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.